Navigation Links
Market Briefing: Emerging Growth NASDAQ Stocks in the News
Date:10/25/2013

l company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company's pipeline of product candidates includes HEPLISAV, its autoimmune program partnered with GlaxoSmithKline (GSK), its therapy for asthma partnered with AstraZeneca AB (AstraZeneca), and clinical-stage programs for its Universal Flu vaccine and hepatitis B therapy. As of December 31, 2011, its intellectual property portfolio included 18 issued United States patents, claiming compositions and formulations of immunostimulatory sequences (ISS) and Internal Revenue Service (IRS), their methods of use or processes for their manufacture. Find out what is new at DVAX at the following link: http://bit.ly/FeaturedReport-DVAX

Dendreon Corporation (NASDAQ:  DNDN) Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Rec
'/>"/>

SOURCE FN Media Group, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Toronto Stock Exchange Symbol: MS, EDMONTON, June 12 /PRNewswire-FirstCall/ - ... multiple sclerosis (MS), today,announced that Mr. Kevin Giese, President and CEO, ... in San Diego,California., WHEN: ... (PDT), WHERE: ...
... June 12 Repligen Corporation,(Nasdaq: RGEN ) today ... ended March 31, 2008. Total revenue for fiscal year ... fiscal year 2007,ended March 31, 2007, an increase of ... of Protein A and SecreFlo(R) product revenue., Operating ...
... concerning the,economic and business growth in the Tampa Bay ... To Connect Tampa Bay With Mexico, South America, ... cargo service every 60,days between the Port of Tampa ... and Iquitos, Peru. Headquartered in,Lima, Peruvian Amazon Line has ...
Cached Biology Technology:BioMS Medical to present at 2008 BIO International Convention 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8Highlights of Economic and Business Growth in the Tampa Bay Region 2Highlights of Economic and Business Growth in the Tampa Bay Region 3
(Date:4/24/2014)... bacteria attack plants, they often inject harmful proteins ... suppress natural defenses. However, in some plants, bacteria ... a potential host. Now, researchers at the University ... that allows the bacteriaknown mostly for attacking tomatoesto ... natural anti-infective treatments that work with food-producing plants ...
(Date:4/24/2014)... April 24, 2014GEN Publishing recently introduced ... focusing on the application of OMICs technologies in ... sequencing, are beginning to transform medical care just ... the past decade-and-a-half. , "GEN,s editors and reporters ... genomics, metabolomics, transcriptomics, etc. etc. for years," said ...
(Date:4/24/2014)... 24, 2014D-ribose is a commercially important sugar used ... a starting compound for synthesizing riboflavin and several ... to increase the bacteria,s ability to produce ... efficient industrial-scale production of this valuable chemical, as ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):Plants send out signals attracting harmful bacteria, MU study finds 2
... her research into single-cell organisms that affect oral health, ... molecular genetics at The University of Texas Health Science ... the 2011 American Society for Microbiology (ASM) Founders Distinguished ... made significant contributions to the society. Goldschmidt joined the ...
... The University of Pennsylvania, Dr. Ron Koder, assistant professor of ... of a team that devised a novel method for producing ... neuroglobin. He was recently awarded a three-year $1.3 million ... artificial blood that can be administered to injured troops on ...
... Biomedical Research Institute (Seattle BioMed) and Northwestern University Feinberg ... the effort to wipe out some of the most ... large structural genomics centers, they,ve experimentally determined 500 three-dimensional ... pathogens, which could potentially lead to new drugs, vaccines ...
Cached Biology News:UTHealth professor to receive service award from American Society for Microbiology 2CCNY professor gets grant to develop 'artificial blood' 2Milestone in fight against deadly disease 2Milestone in fight against deadly disease 3
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... The VSO LF (Low Flow) offers the same ... control for applications where control is critical or ... solenoid-operated valve automates the flow of gas in ... either DC current or pulse width modulation; closed ...
... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
Biology Products: